Stockreport

NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability

Immuron Limited - American Depositary Shares  (IMRN) 
US:NASDAQ Investor Relations: immuron.com/investor-centre/business-overview
PDF MELBOURNE, Australia, July 10, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company, Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is pleased to announce safety an [Read more]